

:: History

vasopharm was founded in July 1998 as a spin-off from the University of Würzburg Medical School by

Harald Schmidt, MD, PhD

, Professor of Pharmacology and Toxicology, and

Ulrich Walter, MD

, Professor of Clinical Biochemistry and Pathobiochemistry.

July 1998

Foundation of **vasopharm**; Business Model: Fee for Service for the pharmaceutical industry until end of 2000

August 2001

Series A Financing round with 3i Group Investments LP as Lead Investor (EUR 6.5 m)

October 2002

License Agreement with BioCytex, Marseille (Cytometric VASP Assay for Clopidogrel® monitoring)

March 2003

Start of GMP production of VAS203

February 2004

Grant of the Bavarian Research Foundation for Nox inhibitors

October 2004

Patent license agreement with Pfizer Inc., USA

November 2004

New investor Entrepreneurs Fund B.V., Amsterdam

September 2005

CE Mark certification for the cytometric VASP assay

January 2006

Series B Financing round with EMBL Ventures as Lead Investor (EUR 9.7 m)

September 2006

European Commission Grants Orphan Medicinal Product Designation for **vasopharm's** drug candidate VAS203

December 2006

First human study with **vasopharm's** trauma compound VAS203

July 2007

Successful completion of first-in-man study with **vasopharm's** compound VAS203

June 2008

Successful completion of clinical phase Ib study with multiple application of **vasopharm's** compound VAS203

May 2009

Series D Financing round (EUR 4.5 m)